Bao Pharmaceutical Included in the MSCI Global Index Constituents, with Its Innovative R&D Strength Recognised Globally

On 14 May 2026, Bao Pharmaceutical (2659.HK) announced that, according to the index review results published by MSCI on 12 May 2026, the Company has been successfully included as a constituent of the MSCI Global Small Cap Indexes. The relevant adjustment will officially take effect after market close on 29 May 2026.

The MSCI Global Small Cap Indexes are compiled by MSCI Inc. and are designed to measure the performance of representative and investable small- and mid-cap companies across global markets. The MSCI index system is one of the most influential index systems in the world. More than US$17 trillion in assets from global institutional investors track MSCI indices, including sovereign wealth funds, pension funds, mutual funds, and exchange-traded funds (ETFs), among other professional investment institutions. The selection criteria cover key indicators such as market capitalisation, liquidity, industry representation, and corporate governance.

This inclusion marks a further enhancement of Bao Pharmaceutical’s visibility and influence in the global capital markets. It is expected to help the Company’s shares attract broader attention from international investors, bring potential incremental passive fund allocations, and further improve the stock’s market liquidity, trading activity, and international profile.

About Shanghai Bao Pharmaceutical

Founded in 2019, Shanghai Bao Pharmaceutical Co., Ltd. is an innovative biotechnology company specializing in clinical development, synthetic biology and recombinant biologics. The company focuses on replacing traditional biochemically extracted products and upgrading validated therapies, building a diversified pipeline across high-volume subcutaneous drug delivery, autoimmune diseases and assisted reproduction. With leading chassis-cell engineering capabilities, a stable commercial manufacturing system, and an international R&D team, Bao Pharma aims to become a global frontrunner in recombinant biologics.

Forward-Looking Statement

This press release may contain forward-looking statements based on current expectations, assumptions, and projections made by the management of Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”). These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such statements include, but are not limited to, descriptions of business strategies, future operational plans, R&D progress, clinical-trial outcomes, commercial prospects, and financial performance. Except as required by law or regulation, Bao Pharma undertakes no obligation to update or revise any forward-looking statement to reflect new information, future events, or other changes. This press release is for informational purposes only and does not constitute investment advice or an offer to purchase securities of the company.